Evestia Clinical announced on July 15 that it has merged with Charlottesville, Virginia-based Atlantic Research Group.
Atlantic Research Group is a contract research organization (CRO) focused on oncology, immunology and neurology, The company provides comprehensive clinical program development services ranging from planning to commercialization, achieving more than 50 market authorizations to date.
Evestia Clinical is a specialist full-service CRO specializing in clinical trials for oncology and rare diseases. It has office locations in the United States, the United Kingdom and Australia.
The merger expands Evestia Clinical’s global footprint in the United States and broadens its therapeutic and services offering to include neurology and late-stage clinical trial services. The deal immediately more than doubles the size of Evestia Clinical by headcount and service delivery capability. In turn, Atlantic Research Group’s clients will benefit from a seamless transition to Evestia Clinical, with immediate access to its global presence and capabilities including new areas of therapeutic expertise, such as rare diseases.
Atlantic Research Group’s CEO and President will both join Evestia Clinical’s senior leadership team and existing Atlantic Research Group clients will transfer seamlessly to the merged company. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 11th CRO deal of 2025. There were 33 CRO transactions announced during 2024, 44 announced during 2023 and 41 announced during 2022.
